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Context Lung cancer is associated with significant distress, poor quality of life, and a median 
prognosis of less than one year. Benefits of shared decision making (SDM) have been 
described for multiple diseases, either by the use of decisions aids or as part of supportive care 
interventions. 
Objectives To summarize the effects of interventions facilitating SDM on distress and 
healthcare utilization among patients with lung cancer.  
Methods We performed a systematic literature search in the CINAHL, Cochrane, EMBASE, 
MEDLINE, and PsychINFO databases. Studies were eligible when conducted in a population 
of patients with lung cancer, evaluated the effects of an intervention that facilitated SDM, and 
measured distress and/or health care utilization as outcomes.  
Results A total of 12 studies, detailed in 13 publications, were included: nine randomized 
trials and three retrospective cohort studies. All studies reported on a supportive care 
intervention facilitating SDM as part of their intervention. Eight studies described effects on 
distress and eight studies measured effects on healthcare utilization. No effect was found in 
studies measuring generic distress. Positive effects, in favor of the intervention groups, were 
observed in studies using anxiety-specific measures (n=1) or depression-specific measures 
(n=3). Evidence for reductions in healthcare utilization was found in five studies. 
Conclusion Although not supported by all studies, our findings suggest that facilitating SDM 
in the context of lung cancer may lead to improved emotional outcomes and less aggressive 
therapies. Future studies, explicitly studying the effects of SDM by using decision aids, are 
needed to better elucidate potential benefits. 
 




















Lung cancer represents 13% of all cancer diagnoses and remains one of the most 
frequently diagnosed cancers worldwide. It is the leading cause of cancer deaths with a 
median prognosis of less than one year.1 Patients with lung cancer experience high levels of 
distress throughout and after treatment, especially when compared to patients with other types 
of cancer.2,3 Also, the overuse of aggressive therapies (e.g. chemotherapy) near the end of life 
is increasingly regarded as disadvantageous.4–7 Patient-centred conversations earlier in the 
disease course may lead to improved emotional well-being and to care that is aligned with 
patients’ personal preferences.8,9 
To better achieve such conversations, especially when patients are faced with difficult 
treatment trade-offs, an increased emphasis is put on the concept of shared decision making 
(SDM).10,11 Especially in preference-sensitive decisions, such as the decision on whether or 
not to pursue a new course of treatment when faced with a life-limiting illness, SDM is of 
critical relevance.10,12–15 To date however, patient values and personal preferences are not 
routinely integrated in clinical care mainly due to time constraints, unawareness, or 
uncertainty on part of the clinician.13,16,17 In contrast to this, a majority of patients do express 
a desire to have a role in SDM, emphasizing the need to further develop evidence on how to 
facilitate such a process.18–23  
Facilitation of SDM has been shown to improve a patients’ emotional state of well-being, 
increase patient or caregiver involvement, increase decision satisfaction, and possibly reduce 
overly aggressive therapies near the end of life.24,25 In other settings, tools have been 
developed to specifically facilitate SDM in clinical practice.26,27 Such tools, hereafter referred 
to as decision aids, usually inform patients about benefits and disadvantages of different 
(treatment) alternatives. To date however, no study has summarized the effects of SDM in 

















available evidence on the effects of SDM in patients with lung cancer and focused on the 




















Design and data sources 
The review protocol was registered in PROSPERO (CRD42015026954). We 
systematically searched the CINAHL, Cochrane, EMBASE, MEDLINE, and PsychINFO 
databases. Two search updates were performed; the latest update was conducted on 2 May 
2018. Terms used in our electronic search strategy were shared decision-making, lung cancer, 
distress and healthcare utilization. We decided to use a broad search strategy since no MESH 
heading for “shared decision making” is available. This search strategy included both subject 
headings and free text terms and was adjusted for the use of synonyms and alternative 
spellings (Supplement A). A librarian assisted this process. All references were exported to 
RefWorks, ProQuest LCC, 2017 and duplicates were removed. We adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist throughout 
the reporting of our study.28   
 
Eligible studies 
Two investigators (MES and OPG) independently performed an initial screening based on 
title and abstract. The same investigators performed a full-text appraisal of the remaining 
studies to determine final inclusion. Reference lists of all included studies were hand searched 
for additional studies. Disagreements were resolved through a consensus discussion with a 
third independent investigator (AJB). Studies were eligible for inclusion if all of the following 
criteria were met:  
 
1) The study contained original data;  
2) The study included ≥100 patients with a confirmed diagnosis of lung cancer; authors of 

















separately on the subsample of lung cancer patients were approached for data on the lung 
cancer patients; 
3) The study explicitly detailed on the facilitation of SDM, either as part of a supportive 
care intervention or by use of a decision aid; 
4) SDM had to be facilitated throughout treatment-related decisions: studies reporting on 
decision rules for clinicians, decisions on lifestyle changes only, clinical trial entry, or 
education programs not geared towards a specific decision were excluded; 
5) The study had a control group in which patients received usual care, we accepted both 
randomized and non-randomized studies; 
6) At least one outcome measure of distress and/or healthcare utilization was used.  
 
We used the definition as provided by Towle et al.11 to delineate SDM: A process to make 
decisions that are shared by both doctor and patient by informing patients using best 
evidence about risks and benefits including patient-specific characteristics and values. 
Distress was defined as: “emotional and/or physical distress measured by a generic 
distress scale and/or a scale measuring symptoms of depression or anxiety”.29 
Questionnaires measuring distress were considered to quantify generic distress if two or 
more of the following domains were covered: physical problems, spiritual problems, 
social problems, or symptoms of anxiety or depression. We defined healthcare utilization 
as “any measure quantifying the amount of care a patient may have received” (e.g. the 
number of hospitalizations throughout the study period or whether a patient received 
chemotherapy in the last 30 days of life). The time period as defined by the study was 
used. Since healthcare utilization may be expressed in many different ways, we decided to 

















across all included studies. All other outcomes and results related to healthcare utilization 
are provided in Supplement B. 
 
Data extraction and statistical analysis 
A standardized data extraction form following the CONSORT criteria30,31 was developed 
to synthesize the data of selected studies. The extraction form consisted of nine items 
assessing study methodology (e.g. study design and the follow-up period) and six items 
evaluating the study’s results (e.g. flow of participants throughout the study and numbers of 
participants analyzed). Whenever multiple measures of one outcome (e.g. different 
questionnaires to quantify distress) were used, we extracted data from all measures. Different 
publications detailing on the same study population were analyzed as one study. We expected 
that pooling of results in a meta-analysis would not be feasible due to intervention- and 
outcome measures heterogeneity. When the number of studies included was considered too 
small to perform subgroup analyses, the ‘best evidence’ approach was performed including an 
analysis of the strength of evidence.32  
Clinical relevance was assessed based on available literature regarding the “Minimally 
Clinical Important Difference” (MCID). The following MCID’s and cutoff scores were used: 
+3 for the Edmonton Symptom Assessment System (ESAS),33,34 +1.5 for the Hospital 
Anxiety and Depression Scale (HADS) or a subscale cutoff of >7 with a minimal 5% 
difference between study groups,35 a cutoff of >4 for the Brief Distress Thermometer (BDT) 
with a minimal 5% difference between study groups,36 and a minimal change of 50% from 
baseline score for the Patient Health Questionnaire-9.37 An MCID or cutoff score for the 
Symptom Distress Scale (SDS) was not found. Therefore, we applied the rule of half a 


















Risk of bias assessment 
 
The Cochrane Collaborations’ Risk of bias tool was used to assess risk of bias.41 Using 
this tool, seven aspects that may be subject to bias were assessed: 1) random sequence 
generation, 2) allocation concealment, 3) blinding of participants or personnel, 4) blinding of 
outcome assessors, 5) incomplete outcome data, 6) selective outcome reporting, and 7) other 
potential sources of bias including unbalanced groups at baseline. This tool is primarily 
designed to assess risk of bias in RCTs. For uniformity, we decided to also use this tool in 
other studies and score RCT-specific aspects as non-applicable.  
Risk of bias of included studies was assessed and reported in a standardized spreadsheet 
by two independent investigators (MES and OPG or MES and AJB). For each category, the 
risk of bias was assessed as low, high, or unclear. Discrepancies were resolved by consensus 




















The search yielded 4929 titles and was reduced to 3633 titles after removing duplicates. 
Of these, 92 titles met the criteria for a full text review. A total of 12 eligible studies, reported 
in 13 publications, were included: nine randomized controlled trials (RCTs) and three 
retrospective cohort studies (Figure 1).25,42,51–53,43–50 Three of the RCTs were performed in 
mixed cancer populations.42,43,50 Comparison of the subsamples of patients with lung cancer 
vs. the total study samples showed that patients with lung cancer suffered from more distress 
when compared to the total sample (data not shown). Pooling of results in a meta-analysis was 
not performed due to intervention- and outcome measures heterogeneity.  
 
Description of interventions 
All included studies detailed on a supportive care intervention facilitating SDM as part of 
the intervention. None of the included studies described the effects of a decision aid. Overall, 
the goal of such multi-component interventions was to provide earlier and systematic access 
to palliative care services through either specially trained advanced practice nurses, a 
registered nurse case manager, or members of a palliative care team. Interventions were 
primarily aimed at improving emotional well-being and QoL by encouraging self-
management, addressing symptom burden, and discussing unmet needs. Table 1 provides 
further details on the characteristics of the included studies (13 publications).  
 
Measures of distress 
Effects on distress are summarized in Table 2 and the data below are displayed as 
intervention group (group for which SDM was facilitated) vs. control group. Eight RCTs, 

















studies measured generic distress using either  the ESAS,42,50 the HADS total score, 44,47 the 
BDT,47 or the SDS.48 Four studies measured anxiety, all using the HADS-A subscale.25,44,46,49 
Five studies measured depression and used either the Center for Epidemiologic studies 
Depression Scale (CES-D),42 the Patient Health Questionnaire (PHQ-9),25,46,49 or the HADS-
D subscale.25,44,46,49 Only statistically significant differences are detailed below. Based on the 
previously described MCID’s, clinically relevant differences are displayed in Table 2. 
 
Effects on distress 
Generic distress 
None of the five studies measuring generic distress showed statistically significant 




Of the four studies measuring anxiety, one study (n=150) showed a significantly lower 
percentage of patients with symptoms of anxiety after 12 weeks in the intervention group 
(17% vs. 27%; p<0.05).49 Another study (n=151) showed the same trend but there was no 
significant difference (25% vs. 30%; p=0.66).25 The other two studies showed no significant 
differences in mean anxiety scores.44,46 
 
Depression  
Three out of five studies measuring depression observed beneficial effects favoring the 
intervention group. Two studies (n=151 and n=150) showed a significantly lower proportion 
of patients with high levels of depression as measured with the HADS-D (16% vs. 38%; 

















in the PHQ-9 scores (data not shown) as did the third study (n=191): mean depression scores 
on the PHQ-9 at both 12 weeks (5.61 vs. 7.21; p=0.04) and 24 weeks (5.54 vs. 6.71; 
p=0.05).46 The latter study showed no effect in the HADS-D.46 The two other studies 
compared mean depression scores and observed no significant differences.42,44  
 
Measures of healthcare utilization 
Effects on healthcare utilization are summarized in Table 3 and the data below are 
displayed as intervention group (group for which SDM was facilitated) vs. control group. 
Eight studies, reported in nine publications and detailing on data from 2914 patients, 
described effects on healthcare utilization: five RCT’s25,42–45,48 and three retrospective cohort 
studies.51–53 Across these studies, effects on hospitalizations (n=7),25,42–45,48,52 emergency 
department (ED)-visits (n=5),25,42–45,48 and the use of chemotherapy (n=5)25,43–45,51,52 were the 
three most frequently used outcomes and are summarized in detail below. All other outcomes 




Two of the retrospective studies found evidence for changes with regard to 
hospitalizations. One of these studies (n=286) compared the percentage of patients that were 
hospitalized in the last three months before death, across patients receiving early palliative 
care, late palliative care, or no palliative care (73% vs. 97% vs. 88%; p=0.03).52 The other 
study (n=1476) observed that patients who had received a palliative care consultation had a 
longer mean length of stay (16.3 days vs. 8.3 days; p<0.001).53 The five RCTs detailing on 
this showed no significant differences for hospitalizations between intervention and control 

















favoring the intervention groups, was observed in the percentage of hospitalized patients in 
the last 30 days of life: 37% vs. 54%; no p-value provided, and 47% vs. 56%; p=0.23.25,44 
 
Emergency department visits 
 
One RCT (n=201) found that the cumulative incidence of patients admitted to the ED was 
lower in the intervention group (39% vs. 53%; p=0.02).43 Similar trends, although not 
significant, were observed in two other RCTs (ED-visits in last 30 days of life: 22% vs. 30%; 
no p-value provided, and 25% vs. 38%; p=0.09).25,44 The remaining two studies did not find 
differences between the mean number of ED-visits in both study groups.42,48 
 
Use of chemotherapy 
One RCT (n=223) and one retrospective cohort study (n=286, analyzing early palliative 
care vs. late palliative care vs. no palliative care) reported a significantly lower proportion of 
patients in the intervention group who received chemotherapy in the last 30 days of life: 12% 
vs. 26%; p=0.03 and 14% vs. 40% vs. 28%; p=0.003, respectively.44,52 Another RCT (n=151) 
found similar effects when analyzing the use of chemotherapy in the last 60 days of life (53% 
vs. 70%; p=0.05) and a trend in the last 30 days of life 30% vs 43%; p=0.14.25,45 The other 
two studies did not observe significant differences in the use of chemotherapy, either as 
measured by the mean duration of chemotherapy or by the number of chemotherapy 
treatments.43,51  
 
Risk of bias  
Assessment of the risk of bias of individual studies is shown in Figure 2. Overall, the risk 
of selection bias and attrition bias was perceived as low in most RCT’s. A high risk of bias 

















studies due to the nature of the interventions. Reporting bias was unclear in some studies 
since not all study protocols were made publicly available online prior to publication. In two 
retrospective studies, the study groups were not comparable thereby making selection bias 




















To our knowledge, this is the first systematic review synthesizing evidence on the effects 
of SDM on distress and healthcare utilization in patients with lung cancer. We identified 12 
studies, detailed in 13 publications, describing the effects of supportive care interventions that 
facilitated SDM as part of their intervention. We found no statistically significant differences 
in distress in studies using a generic measure. However, mixed effects, in favor of patients for 
which SDM was facilitated, were found in studies specifically measuring depression or 
anxiety. Regarding reductions in healthcare utilization, we observed some evidence that SDM 
leads to reductions in healthcare use. 
 
A number of observations are of importance. As the incorporation of SDM is 
increasingly propagated for different diseases in order to truly provide patient-centered 
care,54–56 we found evidence that it may lead to less depression and anxiety and reductions 
in healthcare use. This suggests that involving patients in treatment decisions earlier in the 
disease course may lead to care that is better aligned with patients’ personal preferences 
and consequently to improved patient-reported outcomes. Yet, since all included studies 
described multicomponent supportive care interventions, we are not able to deduce 
whether SDM or other components of these interventions (e.g. earlier referrals or 
improved symptom management) account for the observed effects. Clearly, palliative care 
may also improve outcomes related to distress and healthcare utilization without the 
explicit facilitation of SDM. This is especially relevant since we were unable to measure 



















Unfortunately, we did not identify any studies solely describing the effects of the use of a 
decision aid for patients with lung cancer. Several relevant pilot studies described the design 
and pilot testing of such tools.57–60 These studies all conclude that facilitating SDM in clinical 
practice is feasible. Moreover, two of these studies provided preliminary evidence for 
reductions in distress, enhanced patient satisfaction, better symptom control, and improved 
disease knowledge and understanding.59,60 Such tools have yet to be tested in larger cohorts of 
patients with (lung) cancer.  
We found several research protocols describing interventions aimed at testing the effects 
of decision aids in patients with different types of (advanced) cancer.61–64 Additionally, two 
recent systematic reviews concluded that the evidence base for SDM is at a relatively early 
stage.26,27 These studies summarized the use of decision aids for patients facing health 
treatment or screening decisions26 and patients with a life-limiting illness.27 Both reviews do 
provide strong evidence on improved health-literacy and some evidence for reductions in 
decisional conflict.26,27  
 
Strengths of the current review include the use of an extensive, systematic search strategy 
in five widely used databases from founding date through May 2018. We therefore believe the 
chance of having missed relevant studies is small. In addition, by limiting our inclusion of 
eligible studies to patients having received a diagnosis of lung cancer, our results provide 
important information on a relatively homogeneous patient population. Lastly, we adhered to 
the evidence-based PRISMA guidelines, thereby improving our study’s reporting structure.28  
Several limitations of this review deserve consideration. A number of studies in this review 
were powered to detect effects for a larger sample with different types of cancer being 
included. This might have resulted in insufficient power to detect effects in the subsample of 

















possible due to heterogeneity of interventions and outcomes. Clinical relevance, however, is 
not effected by sample size and was clearly defined for most questionnaires in our study. 
Furthermore, we decided to focus on effects of SDM on distress and healthcare utilization. 
We specifically opted for these outcomes since patients with lung cancer are faced with a poor 
prognosis, are highly distressed, and face difficult treatment choices when approaching the 
end of life.65,66 The observation that subsamples of patients with lung cancer experienced 
higher levels of distress further supports this notion. Evidently, other outcomes such as quality 
of life, patient knowledge or patients’ decisional satisfaction are also of relevance in this 
setting. Such outcomes were not included in the current study but should be a target of future 
studies, especially when SDM is explicitly facilitated through the use of a decision aid.  
 
More work in this context is clearly needed. Development of a MESH term specifically 
detailing on SDM would be useful in the future. We had to perform a relatively broad search, 
including 49 terms to fully cover the concept of shared decision making and to ensure that all 
eligible studies were identified. Further, randomized studies may not be the most optimal 
mode to study potential benefits of SDM. This could especially be true for patients with lung 
cancer since the disease course is unpredictable and patients are faced with a poor prognosis. 
Yet, despite the relatively small differences, we did find positive effects on emotional 
outcomes (e.g. anxiety and depression) and healthcare use. In light of the overuse of 
aggressive therapies near the end of life,65,67,68 facilitating SDM in the context of lung cancer 
may lead to improved well-being and better alignment of care to patients’ personal 
preferences. Future studies should attempt to establish such associations and explicitly focus 
on measuring the effects of a decision aid, possibly by measuring the achievement of 
personalized goals. Ultimately, such studies could further elucidate mechanisms on how to 
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Figure 1: Flow chart reporting on selection of articles based on the Flow Diagram by the 
PRISMA Statement 
Figure 2: Risk of bias assessment 


















Table 1: Characteristics of included studies  
Source Study design 
 
Study population  Setting Follow-up SDM intervention Control group Primary 
outcome(s) 
Bakitas et al. 
(2009)† 
 





Norris Cotton Cancer 
Center, affiliated 
outreach clinics and VA 
Medical Center 
 




13 months or until 
death 
Telephone based case 
management, educational 




Allowed to use all 
oncology and supportive 
services without 
restriction 







Basch et al. 
(2016)† 
 
RCT 201 patients starting 
with chemotherapy 







New York City, New 
York, USA 
 
Median 3 months 
(range: 0.25 to 49 
months) 
Web-based self-report of 
symptom burden, email 
alerts to nurses, symptom 
report printed at each clinical 
visit for both nurse and 
oncologist. 




documented in the 
medical record during 
clinical encounters 




quality of life: 
EuroQoL EQ-5D 
Geerse et al. 
(2016) 
 
RCT 223 patients with 
newly diagnosed or 










25 weeks Distress thermometer and 
problem list before 
outpatient visit, followed by 
face-to-face meeting with 
psychosocial nurse and 
referral if appropriate 
 
Medical and 
psychosocial care as 
offered by treating 
physician every 3 weeks 
Quality of life: 
EORTC-QLQ-C30 
Temel et al. 
(2010) and 
Greer et al. 
(2012) 
 
RCT 151 patients with 
newly diagnosed, 
metastatic non-small 












18 months  
Attention to physical and 
psychosocial symptoms, 
establishing goals of care, 
assisting with decision 








Not scheduled to meet 
with the palliative care 
service unless a meeting 
was requested by the 


























Source Study design 
 
Study population  Setting Follow-up Intervention group Control group Primary 
outcome(s) 
Temel et al. 
(2017)† 
 











12 weeks and 24 
weeks 
Outpatient palliative care at 
visit at least once a month 
Usual oncology care, 
able to meet PC clinician 
only upon request. 
 
 
Quality of life: 





al. (2013)  
 
RCT 108 patients with 








12 weeks Meeting individualized 
unmet needs of patients by 
providing information and 
support 
 









Yount et al. 
(2014)  
 
RCT 253 patients with 
stage III or IV non-
small cell lung 






Center, John. H. Stroger 
Jr. Hospital  
 
Chicago, Illinois, USA 
 
12 weeks Weekly monitoring of 
symptoms with reporting to 







Zhuang et al. 
(2018) 
RCT 150 patients with 
diagnosed non-small 
cell lung cancer 
First People’s Hospital 
of Xianyang City 
 
Xi’An, Shaanxi, China 
12 weeks Early palliative care by 
board-certified palliative 
care physicians and 
advanced-practice nurses  
 





et al. (2014)†  
 









4 months (1) Multidisciplinary 
assessment of symptoms, 
distress, and support (2) 
Telephone contact with 
palliative care nurse (3) 
Palliative care follow-up (4) 
A 24 on-call telephone 
service 
 
No formal intervention, 
but palliative care 
referral was not denied, 
if requested 
 
Quality of life: 
FACIT-Sp 
 















- Early palliative care 






Standard oncology care 




















Abbreviations: FACT-G Functional Assessment of Cancer Therapy-General. FACT-L: Functional Assessment of Cancer Therapy-Lung cancer. FACIT-Sp: Functional Assessment of Chronic Illness Therapy - 
Spiritual Well-Being. ESAS: Edmonton symptom assessment system. EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 36. RCT: randomized 
controlled trial. 
† The complete study included a larger sample of patients with different types of cancer. Data of the subsample of patients with lung cancer is displayed in this table 
‡ Data were analyzed and displayed as three groups: early palliative care (>3 months before death), late palliative care (<3 months before death), or no palliative care 
  
Source Study design 
 
Study population  Setting Follow-up Intervention group Control group Primary 
outcome(s) 




cohort study  
286 patients with 
histologically 
confirmed non-small 
cell lung cancer 
Nordland Hospital Trust 
Bodo Center 
 
Bodo, Salten, Norway 
 
 
- Received either early or late 
palliative care throughout the 
study period 
Did not receive palliative 












1476 patients with 
primary or secondary 









- Received a palliative care 
consultation 





















Table 2: Effect of included studies on general distress measures, anxiety-specific measures, and depression-specific measures 
Source General distress  Anxiety  Depression 
 
Bakitas et al. (2009)† ESAS linear mixed model analysis 
p=0.72 
ESAS mean score after 4 months 




CES-D Linear mixed model analysis 
p=0.39 
 
CES-D mean score after 4 months 11.1 vs. 11.6 
p=0.92  
Geerse et al. (2016) 
 
HADS-Total mean change score at 25 weeks 
-2.1 vs. -2.4, p=0.85 
 
HADS-A mean change score at 25 weeks  
-1.3 vs. -1.3, p=0.98 
HADS-D mean change score at 25 weeks 
-0.6 vs. -0.9, p=0.77 
Temel et al. (2010)  
 
- 
HADS-A percentage above cutoff score at 12 weeks  
25% vs. 30%*, p=0.66 
 
HADS-D percentage above cutoff score at 12 weeks 
16% vs. 38%*, p<0.01 
 
PHQ-9 percentage above cutoff score at 12 weeks 
4% vs. 17%*, p=0.04 
 
Temel et al. (2017)† 
 
- 
HADS-A mean score after 12 weeks  
4.47 vs. 5.23‡ 
 
HADS-A mean score after 24 weeks  
4.63 vs. 5.24‡ 
PHQ-9 adjusted mean score at 12 weeks 
5.61 vs. 7.21, p=0.04 
 
PHQ-9 adjusted mean score at 24 weeks 
5.54 vs. 6.71, p=0.05 
 
HADS-D mean score after 12 weeks 
4.90 vs. 5.26‡ 
 
HADS-D mean score after 24 weeks 
4.44 vs. 5.03‡ 
 
Schofield et al. (2013)  
 
HADS-total mean score 12 weeks post-treatment 
11.52 vs. 10.34, p=0.48 
 
BDT mean score 12 weeks post-treatment 
2. 85 vs. 2.99, p=0.81 
 
- - 
Yount et al. (2014)  
 
SDS mean score at 12 weeks adjusted for baseline 







































Data on group for which SDM was facilitated vs. control group are displayed. Abbreviations: BDT: Brief Distress Thermometer. CES-D: Center for Epidemiological Studies Depression Scale. ESAS: Edmonton 
Symptom Assessment Scale. HADS-A: Hospital Anxiety and Depression Scale – Anxiety. HADS-D: Hospital Anxiety and Depression Scale – Depression. PHQ-9: Patient Health Questionnaire. SDS: Symptom 
Distress Scale  
† The complete study included a larger sample of patients with different types of cancer. Data of the subsample of patients with lung cancer is displayed in this table. 
‡ No p-value provided, but according to authors no significant difference 
* Clinically relevant outcome. 
 
 
Zhuang et al. (2018) 
 
- HADS-A percentage above cutoff at 12 weeks 
17% vs. 27%*, p<0.05 
HADS-D percentage above cutoff at 12 weeks 
19% vs. 32%*, p<0.001 
 
PHQ-9 percentage above cutoff at 12 weeks 
9% vs. 16%*, p<0.001 
 
 
Zimmermann et al. 
(2014)† 
 
ESAS change from baseline score 3 months: -0.62 
vs. 0.42, adjusted difference 1.01, p=0.81 
 
ESAS change from baseline score 4 months: -1.97 



















Table 3: Effects on hospitalizations, emergency department visits, and use of chemotherapy  
Source 
 
Hospitalizations Emergency department visits Use of chemotherapy 
Bakitas et al. (2009)† 
 
Number of days in hospital between randomization 
and reference date‡  
3.1 days vs. 2.2 days, p=0.66 
 
Mean number of ED visits between randomization and 
reference date‡ 
0.5 vs. 0.4, p=0.81 
- 
Basch et al. (2016)† 
 
Hospitalizations (cumulative incidence at one year) 
52% vs. 56% p=0.40 
ED visits (cumulative incidence at one year) 
39% vs. 53%, p=0.02 
Mean duration of chemotherapy  
7.49 vs. 5.64 months vs 7.49, p=0.10 
 
Median duration of chemotherapy  
3.47 vs. 2.76  months, p=0.35 
 
Geerse et al. (2016) Hospitalizations between randomization and death: 
73% vs. 76%, p=0.61 
 
Hospitalizations in last 14 days of life 
33% vs. 43%, p=0.22 
 
Hospitalizations in last 30 days of life 
47% vs. 56%, p=0.23 
 
ED visit(s) between randomization and death 
58% vs. 69%, p=0.15 
 
ED visit(s) in last 14 days of life 
18% vs. 25%, p=0.28 
 
ED visit(s) in last 30 days of life 
25% vs. 38%, p=0.09 
 
Chemotherapy in last 14 days of life 
4% vs. 11%, p=0.10 
 
Chemotherapy in last 30 days 





King et al. (2016) 
 
- - Chemotherapy ≥ 2 lines 
48% vs. 52%, adjusted OR 1.12, p=0.71 
 
Chemotherapy in last 14 days of life 
4% vs 4%, adjusted OR 0.94, p=0.93 
 
Chemotherapy in last 30 days of life 
11% vs. 17%, adjusted OR 0.66, p=0.38 
 
Nieder et al. (2016)φ Hospitalized in the last 3 months of life 
73% vs. 97% vs. 88%, p=0.03 
 
- Receipt of active anticancer treatment in the last month of 
life 
14% vs. 40% vs. 28%, p=0.003 
Reville et al. (2010) 
 
Mean length of stay: 16.3 days vs. 8.3 days, 
p<0.001 
  
Median length of stay 












































Data on group for which SDM was facilitated vs. control group are displayed. Abbreviations: ED: Emergency Department. OR: Odds Ratio, provided with 97% confidence interval. 
† The complete study included a larger sample of patients with different types of cancer. Data of the subsample of patients with lung cancer is displayed in this table. 
φ Data were analyzed and displayed as three groups: early palliative care (>3 months before death), late palliative care (<3 months before death), or no palliative care  
‡ Inclusion period: between November 2003 and May 2007. Reference date May 1, 2018. 





Hospitalizations Emergency department visits Use of chemotherapy 
Temel et al. (2010) and 
Greer et al. (2012)‡ 
 
Hospitalizations between randomization and death 
74% vs. 77%§ 
 
Hospitalizations in last 30 days of life 
37% vs. 54%§ 
 
Median length of hospitalization between 
randomization and death 
5.0 days (range 0-50) vs. 7.0 days (range 0-45)§ 
 
ED visit(s) between randomization and death 
53% vs. 57%§ 
 
ED visit(s) in last 30 days of life 
22% vs. 30%§ 
 
Chemotherapy in last 14 days of life 
14% vs. 24%, p=0.18 
 
Chemotherapy in last 30 days of life 
30% vs. 43%, p=0.14 
 
Chemotherapy in last 60 days of life 
53% vs. 70%, p=0.05, adjusted OR 0.47 (0.23-0.99), 
p=0.05 
 
Percentage of participants with a certain number of 
chemotherapy lines 
No chemotherapy 8% vs. 4%, p=0.49;  
One line  28% vs. 37%, p=0.30;  
Two lines 28% vs. 30%, p=0.86;  
Three lines 18% vs. 16%, p=0.83;  
Four or more lines 16% vs. 12%, p=0.64 
 
Yount et al. (2014) 
 
Mean number of hospital admissions during 12 
weeks: 0.62 vs. 0.67, p=0.88 
 
Mean number of ED visits during 12 weeks 















































Supplement A: PICO and Search Strategy 
Participants/population 
 




• Implementation of shared decision making: intervention designed to help people make specific and deliberative choices among options (including the status quo, symptom relief, treatment 
etc.) 
• Use by patients or caregiver 




• Patient group which received usual care 
Exclusions: 
• Studies describing a comparison of SDM tools without a usual care arm 
Outcomes 
1) Distress with symptoms of either: 



















- Quantified by a validated screening instrument (for example the Hospital Anxiety and Depression Scale) 
2) Healthcare utilization 
- Chemotherapy administration 
- Hospital and GP visits 
- Hospitalizations 
- Emergency department visits 
- Hospice services 
- Location of death 
- Documentation of resuscitation preference 
Search 
# 1 Shared decision making 
# 2 Lung cancer 
# 3 Distress 
# 4 Healthcare utilization 
 
# 1 AND #2 AND (#3 OR #4) 
 
Search strings (Medline via EBSCO) 
 
# 1 Shared decision making 
((MH "Decision Making+") OR (MH "Decision Support Techniques+") OR (MH "Decision Support Systems, Clinical") OR (MH "Patient Preference") OR (MH "Patient Care Planning+") 
OR (MH "Needs Assessment") OR (MH "Patient Participation") OR (MH "Patient-Centered Care+") OR (MH "Advance Care Planning+") 
OR 
TI “Treatment decision*” OR TI “decision aid*” OR TI “decision tool*” OR TI “communication aid*” OR TI “decision making” OR TI “decision support” OR TI preference* OR TI “goal* 
of care” OR TI “patient care planning” OR TI “need* assessment*” OR TI “care need*” OR TI “patient* need*” OR TI “patient participation” OR TI “patient centered care” OR TI “patient 
centred care” OR TI “advanc* care planning” OR TI “early palliative care” OR TI “integrated care” OR TI “supportive care” OR TI “integrated palliative care” 
OR 
AB “Treatment decision*” OR AB “decision aid*” OR AB “decision tool*” OR AB “communication aid*” OR AB “decision making” OR AB “decision support” OR AB preference* OR 
AB “goal* of care” OR AB “patient care planning” OR AB “need* assessment*” OR AB “care need*” OR AB “patient* need*” OR AB “patient participation” OR AB “patient centered 



















# 2 Lung cancer 
((MH "Lung Neoplasms+") 
OR  
TI “Lung Neoplasm*” OR TI “Lung Cancer” OR (TI Lung AND TI Cancer) OR TI SCLC OR TI NSCLC OR TI “Lung carcinoma” 
OR 
AB “Lung Neoplasm*” OR AB “Lung Cancer” OR (AB Lung AND AB Cancer) OR AB SCLC OR AB NSCLC OR AB “Lung carcinoma”) 
 
# 3 Distress 
((MH "Stress, Psychological+") OR (MH "Mood Disorders+") OR (MH "Anxiety+") OR (MH "Anxiety Disorders+") OR (MH "Depression") OR (MH "Depressive Disorder+") 
OR 
TI Distress OR TI “Symptom burden” OR TI Mood* OR TI Anxiety OR TI Depressi* OR TI  
LCSS OR TI “Lung cancer symptom score” OR TI “Lung cancer symptom scale” OR TI “Interest question” OR TI “One-question interview” OR TI BAI OR TI BCD OR TI BDI OR TI 
BEDS 
OR TI BSI OR TI “Brief Symptom Inventory” OR TI CES D OR TI DI C OR TI DT/PL OR TI ESAS OR TI “Edmonton Symptom Assessment” OR TI GHQ OR TI “General Health 
Questionnaire” OR TI HADS OR TI HQ OR TI “Hornheide Questionnaire” OR TI IES OR TI “Impact of Event Scale” OR TI “Impact of Event Score” OR TI MEQ OR TI PDI OR TI PHQ 
OR TI “Patient Health Questionnaire” OR TI POMS OR TI PSSCAN OR TI “Psychosocial Screen* for Cancer” OR TI RSCL OR TI “Rotterdam Symptom Checklist” OR TI ZSDS OR TI 
GDS OR TI HRSD OR TI SAS OR TI SDS OR TI STAI OR TI SDS 
OR 
AB Distress OR AB “Symptom burden” OR AB Mood* OR AB Anxiety OR AB Depressi* OR AB LCSS OR AB “Lung cancer symptom score” OR AB “Lung cancer symptom scale” OR 
AB “Interest question” OR AB “One-question interview” OR AB BAI OR AB BCD OR AB BDI OR AB BEDS OR AB BSI OR AB “Brief Symptom Inventory” OR AB CES D OR AB DI 
C OR AB DT/PL OR AB ESAS OR AB “Edmonton Symptom Assessment” OR AB GHQ OR AB “General Health Questionnaire” OR AB HADS OR AB HQ OR AB “Hornheide 
Questionnaire” OR AB IES OR AB “Impact of Event Scale” OR AB “Impact of Event Score” OR AB MEQ OR AB PDI OR AB PHQ OR AB “Patient Health Questionnaire” OR AB POMS 
OR AB PSSCAN OR AB “Psychosocial Screen* for Cancer” OR AB RSCL OR AB “Rotterdam Symptom Checklist” OR AB ZSDS OR AB GDS OR AB HRSD OR AB SAS OR AB SDS 
OR AB STAI OR AB SDS) 
 
# 4 Health care utilization 
((MH "Delivery of Health Care+/UT") OR (MH "Hospitalization+") OR (MH "Hospice Care/UT") OR (MH "Emergency Medical Services+/UT") OR (MH "After-Hours Care+/UT") OR 
(MH "Health Services Administration+/UT") OR (MH "Intensive Care Units+/UT") OR (MH "Terminal Care+") OR (MH "Palliative Care") 
OR  
TI “Healthcare utilization” OR TI “Healthcare utilization” OR TI “Resource* use” OR TI “Chemotherapy administration*” OR TI Hospitalization* OR TI Hospitalisation* OR TI “Hospital 
visit*” OR TI “Hospital day*” OR TI “Location of Death” OR TI “Death location” OR TI 
“Emergency Department Visit*” OR TI “ED visit*” OR TI  “General Practitioner visit*” OR TI “GP visit*” OR TI “Intensive Care Unit Day*” OR TI “ICU Day*” OR TI “Terminal care” 


















AB “Healthcare utilization” OR AB “Healthcare utilization” OR AB “Resource* use” OR AB “Chemotherapy administration*” OR AB Hospitalization* OR AB Hospitalisation* OR AB 
“Hospital visit*” OR AB “Hospital day*” OR AB “Location of Death” OR AB “Death location” OR AB “Emergency Department Visit*” OR AB “ED visit*” OR AB “General Practitioner 
visit*” OR AB “GP visit*” OR AB “Intensive Care Unit Day*” OR AB “ICU Day*” OR AB “Terminal care” OR AB “Palliative Care” OR AB “End of life care” OR AB “Care at the end of 



















Supplement B: Other measures of healthcare utilization 
Source 
 
ICU admissions Location of death Hospice Composite score for aggressive 
end of life care 
Other measures 
Bakitas et al. (2009)a 
 
Number of days in ICU 
between randomization and 
reference date: 0.0 days vs 
0.5 days, p=0.16 
 
- - - - 
Basch et al. (2016)a 
 
- - - - - 
Geerse et al. (2016) - Location of death:  
home 73% vs 71%;  
hospital 23% vs 21%, 
nursing home 2% vs 7%, 
hospice 2% vs 1%,   
p=0.59 
 
- Aggressive end of life care in 
last 14 days of lifeb: 46% vs 
37%, p=0.25 
 
Aggressive end of life care in 




King et al. (2016) 
 
- - Hospice enrollment: 84% vs 
74%, adjusted OR 1.86, 
p=0.113 
 
Median hospice length of 
stay: 24 days vs 38.5 days, 
adjusted HR 0.70, p=0.041 
 
 - 
Nieder et al (2016)f - Hospital death: 33% vs. 
47% vs. 50%, 0.28 
- - Documented resuscitation 
preference :100% vs. 87% vs 
76%, p=0.007 
 
Documented earlier than in the 
last 3 months of life: 61% vs 






































































ICU Location of death Hospice Composite score Other measures 
Reville et al. (2010) 
 




- - Discharged to hospice: 6% vs 
41%e 
 
Discharged to skilled nursing 
facility or rehabilitation home 
13% vs 8%e 
 




Temel et al. (2010) 
and Greer et al. 
(2012) 
 
- Location of death:  
home 54.5% vs 65.6%, 
p=0.28;  
inpatient hospice 19.7% vs 
14.8%, p=0.49;  
hospital or nursing home or 
rehabilitation facility 25.8% 
vs 19.7%, p=0.53 
 
Admission to hospice 
between randomization and 
deathc: 65.7% vs 71.0%, 
p=0.57 
 
Admission to hospice ≤ 3 
days prior to death: 14.7% 
vs 3%e 
 
Admission to hospice > 7 
days before death: 33.3% vs 
60.0%, p=0.004 
 
Median length of stay in 
hospice: 9.5 days vs 24.0 
days, p=0.02 
Aggressive end-of-life-cared: 
54% vs 33%, p=0.05 
 
- 
Yount et al. (2014) 
 
- - -  Mean number of unscheduled 
clinic visits during 12 weeks: 
0.25 vs 0.41, p=0.13 
 
Mean number of phone calls 
to physicians during 12 weeks: 
0.81 vs 0.85, p=0.32 
 
Mean number of phone calls 
to nurses during 12 weeks: 
1.14 vs 1.79, p=0.02 
      
 

















Data on usual care group versus intervention group are displayed. Abbreviations: OR: Odds Ratio, provided with 97% confidence interval. HR: Hazard Ratio: provided with 95% confidence interval 
a
 The complete study included a larger sample of patients with different types of cancer. Data of the subsample of patients with lung cancer is displayed in this table. 
b Patients receiving chemotherapy, being hospitalized, or visiting the ED within either the last 14 or 30 days before death were documented as having received aggressive end-of-life care 
c
 Median duration of follow up among participants who died 5.7 months. 
d
 Patients receiving chemotherapy within 14 days before death, no hospice care, or admission to hospice 3 days or less before death were documented as having received aggressive end-of-life care 
e
 No p-value provided 
f 














PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 















PRISMA 2009 Checklist 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
9 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  10 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
11 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  10 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  12 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
14 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
17 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
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